(CercleFinance.com) – Eli Lilly and Company announced yesterday the availability of a new citrate-free formulation of Taltz (ixekizumab).
The laboratory specifies that this new formulation, approved by the United States Food and Drug Administration in May 2022, contains the same active ingredient as the original formulation.
According to Eli Lilly, the new Taltz formulation significantly reduced injection site pain experienced by some people with an 86% decrease in pain on a visual analog scale (VAS).
Taltz is approved to treat adults and children six years of age and older with moderate to severe plaque psoriasis.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
